DXCMHealthcare · Medical DevicesThe 29 Wall Street analysts covering DexCom, Inc. hold a median 12-month price target of $97 — +9.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 97 of 100 as at 3 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores DexCom, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Issuance (99): The share count has been shrinking and the company is not leaning on new borrowing.
Accruals (64): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Size (7): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on DXCM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +9.1% from it.
Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 31 Oct 2026 | Canaccord Genuity | Maintains | Buy | — |
| 31 Oct 2026 | UBS | Maintains | Buy | — |
| 30 Oct 2026 | Barclays | Maintains | Overweight | $115 → $120 |
| 30 Oct 2026 | Canaccord Genuity | Maintains | Buy | $90 → $97 |
| 30 Oct 2026 | JP Morgan | Maintains | Neutral | $82 → $85 |
| 30 Oct 2026 | StoneX | Maintains | Buy | $82 → $93 |
| 30 Oct 2026 | UBS | Maintains | Buy | $102 → $107 |
| 12 Oct 2026 | BTIG | Maintains | Buy | $90 → $96 |
| 12 Oct 2026 | BTIG | Maintains | Buy | — |
| 7 Oct 2026 | Barclays | Initiates | Overweight | — |
| 7 Oct 2026 | Barclays | Initiates | Overweight | $115 |
| 1 Oct 2026 | RBC Capital | Maintains | Outperform | $90 → $105 |
| 1 Oct 2026 | RBC Capital | Maintains | Outperform | — |
| 18 Sept 2026 | TD Cowen | Reiterates | Buy | $95 |
| 18 Sept 2026 | TD Cowen | Reiterates | Buy | — |
| 18 Sept 2026 | Truist Securities | Maintains | Buy | $93 → $102 |
| 18 Sept 2026 | Truist Securities | Maintains | Buy | — |
| 4 Aug 2026 | Argus Research | Maintains | Buy | — |
| 4 Aug 2026 | Argus Research | Maintains | Buy | $86 → $96 |
| 3 Aug 2026 | Canaccord Genuity | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
DXCM appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, DexCom, Inc. returned +44.6% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 23% of US stocks
Cheaper than 20% of US stocks
Cheaper than 7% of US stocks
Cheaper than 14% of US stocks
Higher than 56% of US stocks
Higher than 33% of US stocks
Higher than 76% of US stocks
Higher than 83% of US stocks
Higher than 82% of US stocks
Higher than 90% of US stocks
Higher than 94% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
DexCom, Inc. has a market value of $30.9B and an enterprise value of $30.5B.
Revenue in the twelve months to 30 June 2026: $5.0B. The latest quarter grew 11.2% year on year.
Net income over the same four quarters: $999.7M, a 20.1% net margin.
Diluted earnings per share, trailing twelve months: $2.53.
Free cash flow in the twelve months to 30 June 2026: $1.4B.
Trailing P/E: 32.7×; forward P/E: 26.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
DexCom, Inc. employs 11,000 people — $452K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own DexCom, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
DexCom plans to launch its G7 15-day continuous glucose monitoring system in Canada this November. The system offers longer sensor wear and improved convenience.
Why it matters — The Canadian launch may support DexCom’s international growth and patient access.
DexCom launched its “A Letter to Diabetes” campaign for National Diabetes Awareness Month and World Diabetes Day. Throughout November, people touched by diabetes are invited to share letters about their experiences.
Why it matters — The campaign gives DXCM visibility among the global diabetes community and highlights stories about living with diabetes.
The Seeking Alpha item says broader Medicare coverage could expand DexCom’s addressable market for its recurring sensor model, provided the company executes. It also notes longer-wear sensors and planned manufacturing scale increases as factors that could improve margins.
Why it matters — Expanded coverage and manufacturing scale could affect DexCom’s market opportunity and margins.
DexCom shares rose after Q3 earnings and revenue exceeded estimates, margins expanded, and 2026 guidance improved. The excerpt attributes the results to strong U.S. demand and adoption of G7 15 Day.
Why it matters — DXCM watchers may note the reported beat, margin expansion, and improved guidance alongside demand and product adoption.
Seeking Alpha published a transcript of DexCom, Inc.’s Q3 2026 earnings call. The excerpt provides no details about the discussion.
Why it matters — The transcript is a source for DXCM watchers seeking information from the company’s quarterly earnings call, but the excerpt does not describe its contents.
The 29 Wall Street analysts covering DexCom, Inc. have a median 12-month price target of $97, with estimates ranging from $79 to $120. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 29 analysts covering DexCom, Inc., 26 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks DexCom, Inc. 97 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, DexCom, Inc. ranks 97 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (99 of 100).
No one can know that. What the data says: the median 12-month target from 29 analysts implies +9.1% from the last close, and Ticker Nerd's factor model ranks DexCom, Inc. 97 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering DexCom, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DXCM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $79 to $120 over the next 12 months.
DexCom, Inc. returned +44.6% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
DexCom Inc. is a medical device company focused on continuous glucose monitoring systems for diabetes and metabolic health.
The most recent item we track (Zacks Investment Research, 3 Nov 2026): "DexCom to Launch 15-Day G7 CGM System in Canada This November". DexCom plans to launch its G7 15-day continuous glucose monitoring system in Canada this November. The system offers longer sensor wear and improved convenience.
DexCom Inc. is a medical device company focused on continuous glucose monitoring systems for diabetes and metabolic health. Dexcom develops wearable biosensors, transmitters, receivers, and software that provide real-time glucose readings, trend data, and alerts to help users and clinicians monitor glucose levels without routine fingerstick testing. Its current product lineup includes Dexcom G7, Dexcom G7 15 Day, Dexcom G6, Dexcom ONE+, Stelo, Dexcom Share, and Dexcom Follow, along with digital tools and remote monitoring features that support daily diabetes management. The company serves people with diabetes, adults with prediabetes and type 2 diabetes who do not use insulin, and healthcare professionals across the United States and international markets. Headquartered in San Diego, California, DexCom plays a significant role in the diabetes care technology market through its focus on connected glucose sensing and data-sharing solutions.
CEO Mr. Jacob Steven Leach · 11,000 employees · United States · https://www.dexcom.com
